The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs

New antiviral drugs are needed for the treatment of cytomegalovirus (CMV) infections, particularly in immunocompromised patients. These studies evaluated the in vitro and in vivo activity of the non-nucleosidic CMV inhibitor, BAY 38-4766, against guinea pig cytomegalovirus (GPCMV). Plaque reduction...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Schleiss, Mark R., Bernstein, David I., McVoy, Michael A., Stroup, Greg, Bravo, Fernando, Creasy, Blaine, McGregor, Alistair, Henninger, Kristin, Hallenberger, Sabine
Formato: Artigo
Idioma:Inglês
Publicado em: 2005
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2768478/
https://ncbi.nlm.nih.gov/pubmed/15652969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2004.09.004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados